Correlation Between Nuvectis Pharma and Entera Bio

Can any of the company-specific risk be diversified away by investing in both Nuvectis Pharma and Entera Bio at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Nuvectis Pharma and Entera Bio into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Nuvectis Pharma and Entera Bio, you can compare the effects of market volatilities on Nuvectis Pharma and Entera Bio and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Nuvectis Pharma with a short position of Entera Bio. Check out your portfolio center. Please also check ongoing floating volatility patterns of Nuvectis Pharma and Entera Bio.

Diversification Opportunities for Nuvectis Pharma and Entera Bio

-0.77

Correlation Coefficient

Nuvectis Pharma  Entera Bio

Pay attention - limited upside

The 3 months correlation between Nuvectis and Entera is -0.77. Overlapping area represents the amount of risk that can be diversified away by holding Nuvectis Pharma and Entera Bio in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Entera Bio and Nuvectis Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Nuvectis Pharma are associated (or correlated) with Entera Bio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Entera Bio has no effect on the direction of Nuvectis Pharma i.e., Nuvectis Pharma and Entera Bio go up and down completely randomly.

Pair Corralation between Nuvectis Pharma and Entera Bio

Given the investment horizon of 90 days Nuvectis Pharma is expected to under-perform the Entera Bio. But the stock apears to be less risky and, when comparing its historical volatility, Nuvectis Pharma is 1.2 times less risky than Entera Bio. The stock trades about -0.08 of its potential returns per unit of risk. The Entera Bio is currently generating about 0.11 of returns per unit of risk over similar time horizon. If you would invest  187.00  in Entera Bio on February 28, 2024 and sell it today you would earn a total of  45.00  from holding Entera Bio or generate 24.06% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Nuvectis Pharma  vs.  Entera Bio

Nuvectis Pharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Nuvectis Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's fundamental indicators remain comparatively stable which may send shares a bit higher in June 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Entera Bio

Risk-Adjusted Performance

13 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Entera Bio are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Entera Bio showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Nuvectis Pharma and Entera Bio

The main advantage of trading using opposite Nuvectis Pharma and Entera Bio positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Nuvectis Pharma position performs unexpectedly, Entera Bio can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Entera Bio will offset losses from the drop in Entera Bio's long position.

The idea behind Nuvectis Pharma and Entera Bio pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.